Jounce Therapeutics, Inc.
(NASDAQ : JNCE)

( )
JNCE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1352.68m
AMGNAmgen Inc.
0.97%203.881.2%$612.82m
GILDGilead Sciences, Inc.
0.77%69.180.9%$531.67m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$525.80m
BIIBBiogen Inc.
-0.27%337.421.3%$408.79m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$323.01m
ILMNIllumina, Inc.
0.87%312.753.5%$317.65m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$300.57m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$212.97m
TSROTESARO, Inc.
0.03%74.9614.4%$167.91m
INCYIncyte Corporation
-0.32%78.422.5%$149.05m
AAgilent Technologies, Inc.
2.10%72.311.5%$147.46m
EXASExact Sciences Corporation
4.19%78.8025.3%$141.72m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$135.00m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$126.49m

Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat catcer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharmain in 2013 and is headquartered in Cambridge, MA.